StockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to Sell

Oramed Pharmaceuticals (NASDAQ:ORMP) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Saturday.

Separately, HC Wainwright reissued a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Trading Up 1.2 %

Shares of NASDAQ ORMP opened at $2.44 on Friday. Oramed Pharmaceuticals has a 12-month low of $2.00 and a 12-month high of $3.67. The company has a market cap of $98.36 million, a PE ratio of 22.18 and a beta of 1.67. The stock has a 50 day simple moving average of $2.38 and a 200-day simple moving average of $2.41.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd bought a new stake in Oramed Pharmaceuticals during the second quarter worth approximately $40,000. Dimensional Fund Advisors LP raised its stake in shares of Oramed Pharmaceuticals by 52.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after buying an additional 10,774 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Oramed Pharmaceuticals in the 3rd quarter worth $272,000. Renaissance Technologies LLC lifted its holdings in shares of Oramed Pharmaceuticals by 89.0% in the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after buying an additional 108,700 shares during the period. Finally, Murchinson Ltd. boosted its stake in Oramed Pharmaceuticals by 23.2% during the second quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock valued at $4,369,000 after buying an additional 320,495 shares in the last quarter. 12.73% of the stock is currently owned by institutional investors.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.